A Novel PIK3CA Hotspot Mutation in Isfahanian Breast Cancer Patients

REFERENCES

• Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Caner Res 2004;6:229–239.
   PubMed Web of Science ®Google Scholar
• Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler W, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
   PubMed Web of Science ®Google Scholar
• Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004;3:772–775.
   PubMed Web of Science ®Google Scholar
• Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005;24:1477–1480.
   PubMed Web of Science ®Google Scholar
• Pérez-Tenorio G, Alkori L, Olsson B, Waltersson MA, Nordenskjöld B, Rutqvist LE, Skoog L, Stål O. PIK3CA mutations and PTEN loss correlate with similar prognostic factors are not mutually exclusive in breast cancer. Clin Cancer Res 2007;13:3577–3584.
   PubMed Web of Science ®Google Scholar
• Campbell IG, Russel SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA. Mutation of PIK3CA gene in ovarian and breast. Cancer Res 2004;64:7678–7681.
   PubMed Web of Science ®Google Scholar
• Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M, Ferro A, Dalla Palma P, Galligioni E, Marchetti A. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 2007;13:6064–6069.
   PubMed Web of Science ®Google Scholar
• Li SY, Rong M, Grieu F, Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 2005;96:91–95.
   PubMed Web of Science ®Google Scholar
• Kang S, Bader AG, Zhao L, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 2005;102:802–807.
   PubMed Web of Science ®Google Scholar
• Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res 2005;65:10992–11000.
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA 2005;102:18443–18448.
   PubMed Web of Science ®Google Scholar
• Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 2006;103:1475–1479.
   PubMed Web of Science ®Google Scholar
• Zhao L, Vogt PK. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci USA 2008;105:2652–2657.
   PubMed Web of Science ®Google Scholar
• Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M, Ferro A, Dalla Palma P, Galligioni E, Marchetti A. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 2007;13:6064–6069.
   PubMed Web of Science ®Google Scholar
• Benvenuti S, Frattini M, Arena S, Zanon C, Cappelletti V, Coradini D, Daidone MG, Pilotti S, Pierotti MA, Bardelli A. PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat 2008;29:284–288.
   PubMed Web of Science ®Google Scholar
• Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol 2001;14:672–676.
   PubMed Web of Science ®Google Scholar
• Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117–127.
   PubMed Web of Science ®Google Scholar
• Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12:395–402.
   PubMed Web of Science ®Google Scholar
• Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 2010;21:255–262.
   PubMed Web of Science ®Google Scholar
• O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ. Activated phosphoinositide 3-kinase/Akt signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 2010;9:1489–1502.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kanai F, Tada M, Asaoka Y, Guleng B, Jazag A, Ohta M, Ikenoue T, Tateishi K, Obi S, Kawabe T, Yokosuka O, Omata M. Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients. Oncogene 2006;11:2950–2952.
   Google Scholar
• Qiu W, Schonleben F, Li X, Ho DJ, Close LG, Manolidis S, Bennett BP, Su GH. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 2006;12:1441–1446.
   PubMed Web of Science ®Google Scholar
• Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmström PO, Mansukhani M, Enoksson J, Hibshoosh H, Borg A, Parsons R. PIK3CA mutations correlate with hormone receptors, node metastasis and ERBB2 and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005;65:2554–2559.
   PubMed Web of Science ®Google Scholar
• Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt ANJ, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, Grant A. McArthur GA, Christos Sotiriou C. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer. PNAS 2010;107:10208– 10213.
   PubMed Web of Science ®Google Scholar
• Levine DA, Bogmolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI, Boyd J. Frequent mutation of the PI3KCA gene in ovarian and breast cancers. Clin Cancer Res 2005;11:2875–2878.
   PubMed Web of Science ®Google Scholar
• Wu G, Xing M, Mambo E, Huang X, Liu J, Guo Z, Chatterjee A, Goldenberg D, Gollin SM, Sukumar S, Trink B, Sidransky D. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 2005;24:1477–1480.
   Google Scholar
• Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 2007;13:408–414.
   PubMed Web of Science ®Google Scholar
• Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, Bertario L, Leo E, Pierotti MA, Pilotti S. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009;20:84–90.
   PubMed Web of Science ®Google Scholar
• Yavari P, Mosavizadeh M, Sadrol-Hefazi B, Mehrabi Y. Reproductive characteristics and the risk of breast cancer—a case-control study in Iran. Asian Pac J Cancer Prev 2005;6:370–375.
   PubMedGoogle Scholar